Related Experiment Videos
In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against
C R Messick1, J Woodward, S L Pendland
1Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico, USA.
Diagnostic Microbiology and Infectious Disease
|November 21, 1998
Summary
RPR 106972, a pristinamycin combination, shows strong in vitro activity against multidrug-resistant enterococci. Combinations with vancomycin or ampicillin, especially with gentamicin, demonstrate synergistic effects, suggesting potential for treating enterococcal infections.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Multidrug-resistant enterococci pose a significant threat in healthcare settings.
- Novel therapeutic strategies are crucial for combating resistant bacterial infections.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of RPR 106972.
- To assess the synergistic potential of RPR 106972 in combination with vancomycin or ampicillin against multidrug-resistant enterococci.
Main Methods:
- Checkerboard and time-kill assays were employed.
- In vitro susceptibility testing was performed on multidrug-resistant enterococci isolates.
- RPR 106972 was tested alone and in combination with vancomycin or ampicillin +/- gentamicin.
Main Results:
- RPR 106972 plus vancomycin showed synergistic or additive effects in 91% of isolates.
- RPR 106972 plus ampicillin demonstrated synergistic or additive effects in 68% of isolates.
- Adding gentamicin to either combination resulted in synergistic or additive effects in 100% of isolates, with no antagonism observed.
Conclusions:
- RPR 106972 exhibits potent in vitro inhibitory activity against Enterococcus faecium.
- The combination of RPR 106972 with vancomycin or ampicillin, particularly with gentamicin, offers promising therapeutic potential for enterococcal infections.